Answers are grounded in this paper and cite their sources.
The increasing prevalence of invasive fungal infections, the emergence of antifungal resistance, and the limitations associated with conventional antifungal therapies highlight the urgent need for innovative drug-delivery strategies capable of improving therapeutic targeting and selectivity. Despite advances in antifungal nanomedicine, the development of delivery platforms that can specifically recognize fungal structures while maintaining favorable carrier properties remains an important research challenge. Dectin-1, a C-type lectin pattern-recognition receptor encoded by the CLEC7A gene, recognizes β-glucan structures present in the cell walls of numerous clinically relevant fungal pathogens. This molecular recognition mechanism provides an attractive opportunity to develop pathogen-directed nanocarriers. Previous investigations have demonstrated the potential of Dectin-functionalized synthetic liposomes, known as DectiSomes, to enhance interactions with fungal β-glucan-containing structures and improve antifungal drug delivery. However, extending this targeting concept to naturally derived extracellular vesicles represents an interesting direction for further investigation. This research proposal introduces an innovative approach to developing a Dectin-1-functionalized exosome-based platform for targeted antifungal drug delivery. The central concept involves the recombinant production and purification of the carbohydrate-recognition domain (CRD) of murine Dectin-1, followed by its functional presentation on extracellular-vesicle membranes using a DSPE-PEG-mediated surface-engineering strategy. By combining the molecular recognition capability of Dectin-1 with the membrane-based architecture of extracellular vesicles, this approach seeks to establish a novel foundation for the development of fungus-targeting nanocarriers. The proposed research comprises three major stages: (1) recombinant expression and purification of the Dectin-1 carbohydrate-recognition domain using a mammalian expression system; (2) preparation of a Dectin-1–PEG–DSPE conjugate and its incorporation into extracellular-vesicle membranes; and (3) comprehensive physicochemical and functional characterization of the engineered nanosystem. Key evaluation parameters include particle size distribution, morphology, surface characteristics, ligand association, vesicle integrity, and specific binding to β-glucan. Competitive inhibition experiments using soluble β-glucan will further investigate the specificity of the proposed molecular recognition mechanism. The major anticipated contribution of this work is the development and initial validation of a modular, biologically derived, pathogen-recognition platform that may provide a foundation for future antifungal nanotherapeutics. In contrast to conventional non-targeted delivery approaches, the proposed strategy explores the possibility of directing nanocarriers toward fungal β-glucan structures through a defined molecular recognition mechanism. Ultimately, this research aims to bridge the fields of medical mycology, extracellular-vesicle engineering, and targeted nanomedicine. The proposed platform may facilitate future investigations into antifungal drug encapsulation, targeted delivery, improved local drug availability, and the development of alternative therapeutic strategies against challenging fungal infections, including those caused by antifungal-resistant pathogens.
No takes yet. Share an insight, caveat, or question.
Haghani et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: